8-K: Vivos Therapeutics Secures $2.1M via PIPE Offering

Vivos Therapeutics, Inc. announced the closing of a $2.1 million private placement, issuing units of preferred stock and warrants to V-Co Investors 4 LLC and Bigger Capital Fund, LP.

Summary

• Vivos Therapeutics, Inc. closed a private placement (PIPE Offering) on June 30, 2026, raising approximately $2.1 million.
• The offering involved the sale of 3,608,496 units at $0.582 per unit.
• Each unit comprised one share of Series A Convertible Preferred Stock, common stock purchase warrants, and two transferable subscription rights.
• The company received $1 million in cash proceeds, with an additional $1 million from the conversion of a previously issued bridge note.
• The net proceeds are intended for general working capital purposes.
• The Series A Convertible Preferred Stock is convertible into common stock on a one-for-one basis, subject to adjustments and beneficial ownership limitations.
• The warrants have an exercise price of $0.456 per share, a five-year term, and include anti-dilution protection.
• Beneficial ownership limitations are in place for V-Co 4 (19.99%) and Bigger Capital Fund (9.99% or 4.99%).
• The company is obligated to file a resale registration statement for the convertible preferred stock and warrant shares within 45 days of closing and have it declared effective within 90 days.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it provides necessary capital, but the terms of the financing, including warrants and preferred stock, introduce potential future dilution.

Positives

• Successfully raised $2.1 million in capital, strengthening the company's financial position.
• Secured funding through a PIPE offering, indicating investor confidence.
• The conversion of a bridge note streamlines the capital structure.
• Warrants provide potential for future capital infusion upon exercise.
• Anti-dilution protection for warrants and preferred stock conversion mitigates shareholder dilution risk.
• The company has a clear plan to use proceeds for general working capital.

Negatives

• The offering involved convertible preferred stock and warrants, which can lead to future dilution.
• The effective exercise price of warrants ($0.456) is lower than the unit purchase price ($0.582), suggesting a discount.
• The company is subject to significant obligations regarding the resale registration statement, with potential penalties for delays.
• R. Kirk Huntsman, CEO, participated indirectly through an affiliated entity (V-Co 4), raising potential governance questions.
• The subscription rights are contingent on SEC effectiveness of a registration statement, creating uncertainty for their issuance.

Risks

• Future dilution from the conversion of preferred stock and exercise of warrants.
• Potential for significant share price impact if the resale registration statement is not declared effective within the stipulated timeframe.
• Beneficial ownership limitations could restrict the ability of investors to fully exercise their rights.
• The company's reliance on future capital raises through warrant exercises.
• The indirect participation of the CEO in the offering through an affiliated entity could present conflicts of interest.

Future Outlook

The company intends to use the net proceeds from the PIPE Offering for general working capital purposes. The company must also ensure the resale registration statement for the convertible preferred stock and warrant shares is filed and declared effective within specified timelines.

Management Comments

• R. Kirk Huntsman, the Company's Chairman and Chief Executive Officer, participated in the PIPE Offering indirectly through V-Co 4.
• Bradford Amman, Chief Financial Officer, signed the Form 8-K report.

Industry Context

StockSavvy.ai notes that this private placement financing is a common strategy for biotechnology and development-stage companies to secure necessary capital for operations and development, especially when facing stringent Nasdaq listing rules regarding minimum share prices.

Comparison to Industry Standards

• The structure of the financing, involving convertible preferred stock and warrants, is a standard practice in the biotech and pharmaceutical sectors for companies seeking growth capital.
• The exercise price of the warrants ($0.456) being tied to a 'Market Price' calculation (lower of previous day's close or 5-day average) is a common mechanism to comply with Nasdaq Listing Rule 5635(d) concerning minimum price requirements for the issuance of securities.
• The inclusion of beneficial ownership limitations (e.g., 19.99% for V-Co 4, 9.99% for Bigger) is typical to manage potential control issues and ensure compliance with securities regulations.
• The commitment to file a resale registration statement within 45 days and have it declared effective within 90 days aligns with standard expectations for PIPE transactions involving publicly traded securities.

Corporate Governance

Related Party Transactions

• R. Kirk Huntsman, the Company's Chairman and Chief Executive Officer, participated indirectly in the PIPE Offering through V-Co Investors 4 LLC, an entity in which he holds membership interests. His indirect participation amounted to approximately $50,000.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of preferred stock and warrants, and future conversion/exercise. However, the capital infusion may support company growth.
• Investors (V-Co 4 and Bigger Capital Fund): Gain equity stake through preferred stock and warrants, with registration rights for resale. Subject to beneficial ownership limitations.
• Creditors: The capital raise strengthens the company's financial stability, potentially improving its ability to meet obligations.

Next Steps

• File a resale registration statement on Form S-3 (or other appropriate form) for the Registrable Securities (Conversion Shares and Warrant Shares) no later than 45 days after the closing of the PIPE Offering.
• Use commercially reasonable best efforts to cause the Resale Registration Statement to be effective within 90 days of the closing of the PIPE Offering.
• Keep the Resale Registration Statement continuously effective until all Registrable Securities have been sold or are eligible for sale under Rule 144.
• Use net proceeds for general working capital purposes.
• Holders of warrants may exercise them, leading to further capital infusion.

Key Dates

Recommendation

The financing provides much-needed capital, which is positive. However, the terms of the financing, including the issuance of preferred stock and warrants at a discount to the unit price, introduce significant potential for future dilution. The company's ability to execute its plans and meet registration obligations will be critical. Investors should monitor the effectiveness of the resale registration statement and the potential impact of warrant exercises.

Keywords

Vivos Therapeutics, PIPE Offering, Securities Purchase Agreement, Convertible Preferred Stock, Warrants, Capital Raise, Registration Rights, Form 8-K, SEC Filing, Financing